Positive
●
Reuters
●
5 months ago
Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter profit and revenue on Wednesday, helped by strong demand for its eczema drug, Dupixent, and cancer drug, Libtayo, offsetting competitive pressures faced by eye drug Eylea.